CVS Health (NYSE:CVS) Upgraded by ValuEngine to “Hold”

CVS Health (NYSE:CVS) was upgraded by equities researchers at ValuEngine from a “sell” rating to a “hold” rating in a research note issued to investors on Wednesday, ValuEngine reports.

A number of other equities analysts have also commented on the stock. Bank of America raised their price target on shares of CVS Health from $72.00 to $75.00 and gave the stock a “buy” rating in a research report on Thursday, September 12th. Raymond James reissued a “strong-buy” rating and issued a $90.00 price objective (up previously from $80.00) on shares of CVS Health in a report on Wednesday. Mizuho increased their target price on shares of CVS Health from $71.00 to $82.00 and gave the stock a “buy” rating in a research report on Friday, November 8th. Citigroup increased their target price on shares of CVS Health from $72.00 to $83.00 and gave the stock a “buy” rating in a research report on Thursday, November 7th. They noted that the move was a valuation call. Finally, TheStreet raised shares of CVS Health from a “c+” rating to a “b-” rating in a report on Monday, September 9th. Seven research analysts have rated the stock with a hold rating, eighteen have issued a buy rating and one has given a strong buy rating to the stock. The stock has an average rating of “Buy” and an average target price of $77.14.

CVS opened at $74.48 on Wednesday. The company has a debt-to-equity ratio of 1.32, a current ratio of 0.92 and a quick ratio of 0.61. The business has a fifty day simple moving average of $70.91 and a 200 day simple moving average of $61.16. CVS Health has a 1 year low of $51.72 and a 1 year high of $78.06. The company has a market capitalization of $97.92 billion, a PE ratio of 10.52, a price-to-earnings-growth ratio of 1.62 and a beta of 0.88.

CVS Health (NYSE:CVS) last posted its quarterly earnings data on Wednesday, November 6th. The pharmacy operator reported $1.84 earnings per share for the quarter, topping the consensus estimate of $1.77 by $0.07. CVS Health had a return on equity of 15.45% and a net margin of 1.83%. The firm had revenue of $64.81 billion for the quarter, compared to analysts’ expectations of $62.99 billion. During the same quarter last year, the business earned $1.73 EPS. The company’s quarterly revenue was up 36.5% compared to the same quarter last year. Equities analysts anticipate that CVS Health will post 7.03 earnings per share for the current fiscal year.

In other news, CFO Eva C. Boratto sold 8,130 shares of CVS Health stock in a transaction on Thursday, September 12th. The stock was sold at an average price of $65.00, for a total value of $528,450.00. Following the transaction, the chief financial officer now owns 55,273 shares in the company, valued at approximately $3,592,745. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, EVP Joshua Matthew Flum sold 17,703 shares of the business’s stock in a transaction on Monday, September 30th. The stock was sold at an average price of $63.00, for a total value of $1,115,289.00. Following the transaction, the executive vice president now directly owns 36,163 shares of the company’s stock, valued at approximately $2,278,269. The disclosure for this sale can be found here. Insiders sold a total of 129,580 shares of company stock valued at $9,259,536 over the last 90 days. Corporate insiders own 0.53% of the company’s stock.

Several hedge funds have recently made changes to their positions in CVS. Ausdal Financial Partners Inc. grew its holdings in shares of CVS Health by 3.0% during the 3rd quarter. Ausdal Financial Partners Inc. now owns 4,566 shares of the pharmacy operator’s stock valued at $288,000 after purchasing an additional 134 shares during the last quarter. Baldwin Brothers Inc. MA grew its stake in shares of CVS Health by 1.1% during the third quarter. Baldwin Brothers Inc. MA now owns 14,911 shares of the pharmacy operator’s stock worth $941,000 after buying an additional 165 shares during the last quarter. Mutual Advisors LLC grew its stake in shares of CVS Health by 0.8% during the second quarter. Mutual Advisors LLC now owns 20,641 shares of the pharmacy operator’s stock worth $1,125,000 after buying an additional 172 shares during the last quarter. Enterprise Financial Services Corp increased its holdings in shares of CVS Health by 3.7% during the third quarter. Enterprise Financial Services Corp now owns 5,156 shares of the pharmacy operator’s stock worth $325,000 after buying an additional 185 shares in the last quarter. Finally, Cleararc Capital Inc. increased its holdings in shares of CVS Health by 1.0% during the third quarter. Cleararc Capital Inc. now owns 19,579 shares of the pharmacy operator’s stock worth $1,235,000 after buying an additional 191 shares in the last quarter. Institutional investors and hedge funds own 76.74% of the company’s stock.

CVS Health Company Profile

CVS Health Corporation provides health services and plans in the United States. Its Pharmacy Services segment offers pharmacy benefit management solutions, such as plan design and administration, formulary management, retail pharmacy network management, mail order pharmacy, specialty pharmacy and infusion, Medicare Part D, clinical, disease management, and medical spend management services.

Featured Article: Determine Your Level of Risk Tolerance

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for CVS Health (NYSE:CVS)

Receive News & Ratings for CVS Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVS Health and related companies with MarketBeat.com's FREE daily email newsletter.